Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | FSHR | P23945 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6687109 | 1.00 | MAPT (0.58) | MAPTMEN1KMT2ANPSR1FSHR | |
| SCHEMBL29968131 | 0.86 | MAPT (0.51) | MAPTMEN1KMT2ANPSR1LMNA | |
| SCHEMBL6686127 | 0.86 | MAPT (0.51) | MAPTMEN1KMT2ANPSR1LMNA | |
| SCHEMBL6687083 | 0.86 | KMT2A (0.53) | MAPTMEN1KMT2ALMNAPOLB | |
| SCHEMBL29968717 | 0.86 | KMT2A (0.53) | MAPTMEN1KMT2ALMNAPOLB | |
| SCHEMBL6695105 | 0.85 | MAPT (0.54) | MAPTMEN1KMT2ANPSR1LMNA | |
| SCHEMBL6692823 | 0.85 | MAPT (0.47) | MAPTKMT2AFSHRLMNAPOLB | |
| SCHEMBL6690231 | 0.85 | MAPT (0.47) | MAPTMEN1KMT2ANPSR1FSHR | |
| SCHEMBL29968850 | 0.85 | MAPT (0.47) | MAPTMEN1KMT2ANPSR1FSHR | |
| SCHEMBL6695115 | 0.84 | KMT2A (0.47) | MAPTMEN1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | disclosed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | disclosed |